News
EVerMed’s Lead Pipeline EM-001 Adopted into AMED’s Pre-Design...
EVerMed is pleased to announce that our lead pipeline candidate, EM-001, has been selected by the Ja...
News & Events
ニュース & イベント
We develop next-generation therapeutics using the unique biological functions of extracellular vesicles (EVs), aiming for long-lasting and clinically meaningful treatments in respiratory medicine.
News
News
EVerMed Inc. received investment from NISSAY CAPITAL CO.,LTD....
EVerMed Inc. has raised 180 million yen through a third-party allotment of new shares to Nissay Capi...
News
EVerMed Inc. received investment from Summit Pharmaceuticals ...
EVerMed Inc. received investment from SPI as the 2nd closing of its seed round. With this capit...
News
EVerMed Inc. has raised 280 million yen in the 1st close of i...
EVerMed Inc. has raised a total of 280 million yen through a third-party allotment of new shares to ...
News
Option Agreement for drug discovery of extracellular vesicles...
EVerMed Inc. and KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CE...
Get in Touch with Our Team
Examples of Inquiries
- Collaboration or joint research opportunities
- Technology evaluation or licensing inquiries
- Partnership discussions with pharma companies
- Investor or business development inquiries
- Requests for scientific data or technical information